Search Results 881-890 of 21580 for Inhibition
... inhibitor or inducer during study therapy (see Appendix 13.6). Use of a proton pump inhibitor (e.g., dexlansoprazole, esomeprazole, lansoprazole, omeprazole ...
... inhibitors within 30 days of registration; Concurrent treatment with any medications or substances that are potent inhibitors or inducers of CYP3A4, hepatic ...
... inhibitor within 14 days impacted in the presence of a CYP3A4 inhibitor within 14 days of screening. Patient has not remained at stables doses of all drugs ...
Mantle cell lymphoma (MCL) patients must have had anti-CD20 and Bruton's Tyrosine Kinase (BTK) inhibitor. ... inhibitors or (corrected QT interval ...
taking proton pump inhibitors. It's probably 10 percent or more. A ... inhibitor?” is best answered during a discussion with your health care.
Have received any prior treatment with an isocitrate dehydrogenase (IDH) inhibitor ... inhibitor; bevacizumab; or any prior vaccine therapy. Note: Other inclusion ...
This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...
... inhibition of all primary and secondary KIT mutations that commonly occur in GIST. A Study to Assess the MEK Inhibitor Mirdametinib (PD-0325901) in Patients ...
... inhibition of ovulation, intrauterine device, intrauterine hormone-releasing ... inhibitors, glucocorticoids, etc., must be concluded 1 month prior to ...
... inhibitors in this high-risk population. Read More on PubMed. Additional contact information. Non-cancer trials contact form. Phone: 800-664-4542 (toll-free).
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.